Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan

BACKGROUND: Post-approval research or monitoring is important to determine real-world safety of new products; however, evidence is scant for vemurafenib in Japanese patients. In Japan, a unique system is officially obligated to investigate post-approval safety. Here we report the first adverse drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhara, H., Kiyohara, Y., Tsuda, A., Takata, M., Yamazaki, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797186/
https://www.ncbi.nlm.nih.gov/pubmed/28674996
http://dx.doi.org/10.1007/s12094-017-1706-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797186/
https://www.ncbi.nlm.nih.gov/pubmed/28674996
http://dx.doi.org/10.1007/s12094-017-1706-2

Ejemplares similares